

REMARKS/ARGUMENT

Claim 21 has been cancelled. Claims 22, 25, 27, 28 and 31-33 have been amended to correct their dependency.

Claims 20-34 stand rejected under 35 U.S.C. 102(b) as being anticipated by Wolf 156 *Int. J. Pharm.* 97 (1997), the Examiner contending that Wolf discloses a composition of a low solubility drug, a poloxamer, and the polymer hydroxypropyl methylcellulose (HPMC). But independent claim 20 is directed to a composition comprising (a) a low solubility drug, (b) a poloxamer, and (c) a stabilizing polymer selected from hydroxypropyl methylcellulose acetate succinate (HPMCAS) and carboxymethyl ethylcellulose (CMEC). Wolf therefore does not disclose element (c) of independent claim 20. Accordingly, Wolf does not anticipate claim 20. Since all of the remaining claims depend from claim 20, they are likewise not anticipated by Wolf.

Early and favorable reconsideration is respectfully solicited.

Respectfully submitted,



Dennis E. Stenzel
Reg. No. 28,763
Tel No.: (503) 227-5631